The European Medicines Agency (EMA) recently issued an essay outlining the main points of the Pharmacovigilance Risk Assessment Committee (PRAC) conference, which took place from July 3-6, 2023.
The PRAC is in charge of evaluating the safety and monitoring of medical products throughout the European Union. Several key subjects were discussed during the discussion, including a review of safety concerns regarding certain drugs. The committee reviewed available data and made suggestions for regulatory actions, such as product information updates and risk-mitigation strategies. Furthermore, the PRAC assessed and advised on a variety of pharmacovigilance operations, such as signal management and risk communication. The article highlights the EMA's dedication to guaranteeing the safety of pharmaceutical goods and encouraging effective pharmacovigilance methods to protect public health.
